•  
  •  
 

Publication Date

8-14-2015

Keywords

novel oral anticoagulants, atrial fibrillation, deep vein thrombosis, pulmonary embolism, dabigatran, Pradaxa, rivaroxaban, Xarelto, apixaban, Eliquis, edoxaban, Savaysa, Lixiana

Abstract

Novel oral anticoagulants (NOACs) are becoming popular management options for stroke prophylaxis in nonvalvular atrial fibrillation as well as deep vein thrombosis and pulmonary embolism treatment and prophylaxis. NOACs have similar efficacy to warfarin along with noninferior safety profiles. Patient comorbidities, size, renal and hepatic function, and concomitant drug regimen play a role in which NOAC a physician may choose.

Share

COinS
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.